Edesa Biotech, Inc. quarterly report, Q2 FY2017

Filing summary

Issuer and period: The supplied filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter and six months ended March 31, 2017 (fiscal Q2 2017), not an Edesa Biotech filing. Financial amounts are U.S. dollars.

Business context and reporting period

Stellar develops, manufactures and commercializes Keyhole Limpet Hemocyanin (KLH) for immunotherapy and immunodiagnostic applications. It sells primarily to biotechnology and pharmaceutical companies, academic institutions and clinical research organizations. In January 2017, it formed a wholly owned Mexican subsidiary to support aquaculture research and assess a potential second production site.

Financial performance and position

For the six-month period, product sales were $154,875 and contract services revenue was $50,000. R&D expense was $790,236; general and administrative expense was $1,678,427. The filing does not provide a clear standalone gross-margin figure.

At March 31, cash and cash equivalents were $4,601,222, short-term U.S. Treasury investments were $3,994,364, and working capital was $8,915,300. Current assets were $9,348,684 versus current liabilities of $433,384. Total assets were $10,222,989 and shareholders’ equity was $9,789,605. The balance sheet lists no debt; liabilities shown are accounts payable and accrued liabilities. Cash and cash equivalents declined $2,815,682 from September 30, 2016.

Changes versus comparable periods

• Six-month revenue fell $609,620, or about 75%, from $814,495, primarily because sales shifted from larger orders for later-stage clinical studies to lower-volume clinical and preclinical demand.
• Six-month net loss increased to $2,589,349 from $2,490,813, although loss per share improved to $0.26 from $0.30 as the weighted-average share count increased.
• Six-month total expenses declined to $2,766,908 from $3,217,792. Lower sales-related costs and G&A were partly offset by R&D rising to $790,236 from $597,911, chiefly for manufacturing scale-up and aquaculture work.
• Quarterly revenue declined to $63,019 from $326,335, and quarterly net loss widened to $1,103,677 from $861,010. The current quarter included $50,000 of contract services revenue, versus none a year earlier.
• Operating cash use increased to $2,641,197 from $2,247,526 for the six-month comparison. No financing cash was raised in the current period.

Outlook, risks and notable items

• Management said available working capital should fund current requirements, contractual obligations and anticipated R&D for at least 12 months, while also noting continued expected losses and that further capital may be needed. No new financing commitment was secured; availability and terms are uncertain. A $100 million shelf registration statement remained available, subject to applicable issuance limits.
• Management expects clinical-study progression to affect the timing and volume of future KLH sales. Customer concentration is significant: two customers generated 88% of six-month revenue; one customer represented 76% of receivables at quarter-end.
• In February 2017, Stellar entered an exclusive, multiyear KLH supply agreement with Amaran Biotechnology for specified cancer immunotherapy development. The agreement includes field-specific exclusivity and an FDA master-file obligation.
• In March 2017, Stellar terminated its University of Guelph C. diff technology license and transferred related rights and know-how to Matrivax for an upfront payment and a share of certain future amounts. Stellar reported no further Guelph license fees, royalties, milestones or termination penalties.
• Commitments included approximately $503,000 of future minimum lease payments and about $235,000 for CRO and consultant agreements, plus an estimated $27,000 for contractor time and materials. The joint venture agreement includes additional pro-rata funding obligations if required and milestones that could lead to dissolution or other outcomes.
• Management reported effective disclosure controls as of March 31, 2017, no material change in internal control, and no material legal proceedings outside the ordinary course. No material changes to previously disclosed risk factors were reported.

Investor verification priorities

1. Confirm issuer identity: this source is Stellar Biotechnologies, Inc., despite the request metadata naming Edesa Biotech.
2. Track KLH customer orders, clinical-program progression and customer concentration for evidence of revenue recovery or continued volatility.
3. Assess cash burn against management’s 12-month liquidity estimate, and monitor financing needs, shelf capacity and any new capital commitments.
4. Verify progress and costs of manufacturing scale-up and the Mexican aquaculture initiative, as well as the supply agreement’s commercial contribution.
5. Review the consideration and contingent future economics of the Matrivax transfer and the joint venture’s milestone, funding and continuation status.